Article Information
History
- May 17, 2021.
Article Versions
- Version 1 (January 11, 2021 - 18:21).
- Version 2 (April 23, 2021 - 13:30).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Endika Prieto-Fernández1,
- Leire Egia-Mendikute1,
- Laura Vila-Vecilla1,
- Alexandre Bosch1,
- Adrián Barreira-Manrique1,
- So Young Lee1,
- Ana García-del Río1,
- Asier Antoñana-Vildosola1,
- Borja Jiménez-Lasheras1,
- Leire Moreno-Cugnon2,
- Jesús Jiménez-Barbero3,4,5,
- Edurne Berra2,6,
- June Ereño-Orbea3,5 and
- Asis Palazon1,5,*
- 1Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, Spain
- 2Cancer Cell Signaling and Metabolism Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, Spain
- 3Chemical Glycobiology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, Spain
- 4Department of Organic Chemistry II, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain
- 5Ikerbasque, Basque Foundation for Science, Bilbao, Spain
- 6CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
- ↵*Corresponding author: Asis Palazon (apalazon{at}cicbiogune.es).